Marty Makary & Vinay Prasad

Marty Makary: As the Commissioner of the United States — Food and Drug Administration, Marty Makary is a key figure in implementing the new policy to reduce the number of required studies for drug approval, aiming to speed up drug development.

Vinay Prasad: As a top deputy at the United States — Food and Drug Administration, Vinay Prasad co-authored the New England Journal of Medicine piece announcing the change in drug approval requirements. However, he has also taken a more restrictive approach to vaccines and gene therapies, creating some inconsistency.

Marty Makary: Marty Makary>>> resigned as Commissioner of the United States — Food and Drug Administration>>> after a tumultuous tenure marked by clashes with the Donald Trump>>> administration, industry, and public health groups. His departure creates uncertainty for several of his initiatives.

Vinay Prasad: Vinay Prasad>>>, a close ally of Marty Makary>>>, served as the FDA's vaccine and biotech chief but was pushed out twice, contributing to the agency's internal dysfunction and leadership instability.

Marty Makary: Marty Makary resigned as United States — Food and Drug Administration Commissioner, having engineered Tracy Beth Høeg's rapid rise and facing criticism from political allies.

Vinay Prasad: Vinay Prasad, the United States — Food and Drug Administration's vaccine and biotech chief, stepped down amid criticism, having co-written papers with Tracy Beth Høeg and Marty Makary.

Marty Makary: Makary, former FDA Commissioner, faced criticism for vaccine scrutiny and resigned amid controversies.

Vinay Prasad: Prasad's refusal-to-file decision was reversed, and he later left the FDA; his actions highlighted regulatory tensions.

Marty Makary: Makary resigned as FDA commissioner in May after clashes with the White House. His departure created the vacancy Overton is nominated to fill.

Vinay Prasad: Prasad, former FDA vaccine chief, departed in April. His exit is part of the agency's instability.

Vinay Prasad: Dr. Vinay Prasad, director of the United States — Food and Drug Administration's Center for Biologics Evaluation and Research, initially overruled agency reviewers and signed the refusal letter for Moderna's vaccine application, citing concerns about the trial's control arm.